The inflammatory tumor microenvironment (TME) is a complex network of cancer, immune, and stromal cells interacting through cytokines and growth factors to drive tumor growth, angiogenesis, and immune ...

The field of cancer immunotherapy has achieved remarkable progress, introducing strategies such as immune checkpoint inhibitors and adoptive cell therapies ...

Large BIDMC-led study maps immune cells in myeloma tumors, improving risk prediction beyond genetics and helping identify ...

Among the presentations included in the Top Abstracts category at the recently inaugurated Annual Congress of the European Association for Cancer Research (EACR) in Lisbon, it is worth highlighting ...

T cell senescence occurs in the TME, affecting cancer prognosis and immunotherapy efficacy. The TME induces T cell senescence through multiple pathways, including persistent stimulation by ...

A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene ...

Over the past decade, the advent of immune checkpoint blockade (ICB) therapy has transformed cancer treatment. Unlike conventional cytotoxic and targeted therapies, immunotherapy leverages both the ...

As people age, their immune function gradually declines, coinciding with increased cancer rates. However, the precise reasons behind age-related dysfunction of CD8+ T cells in cancer remain unclear.

Cancer neuroimmunology integrates the study of the nervous system's influence on tumor immunity, highlighting an intricate interaction that affects cancer progression and therapeutic outcomes. Recent ...

Cancer immunotherapy has already transformed treatment for some patients, yet too often the body’s defenders stall out before ...